戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 aglandin transporter (PGT) and the enzyme 15-hydroxyprostaglandin dehydrogenase.
2 F(2alpha)), are enzymatically degraded by 15-hydroxyprostaglandin dehydrogenase (15-HPGD).
3                                           15-Hydroxyprostaglandin dehydrogenase (15-PGDH) and 15-oxop
4 igh affinity to the PGE2-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and increas
5 tory cytokine-dependent downregulation of 15-hydroxyprostaglandin dehydrogenase (15-PGDH) and subsequ
6 r cell lines, 4-OXO-DHA induced PPARy and 15-hydroxyprostaglandin dehydrogenase (15-PGDH) but inhibit
7                          NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes t
8                            NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) catalyzes t
9 of the key prostaglandin catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in breast c
10 ase in the prostaglandin-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH) in skeletal
11                                           15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a key en
12                                           15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a metabo
13                                           15-Hydroxyprostaglandin dehydrogenase (15-PGDH) is a prosta
14  requires the concomitant presence of the 15-hydroxyprostaglandin dehydrogenase (15-PGDH) tumor suppr
15           The cDNA for rat NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH) was cloned
16          Here, we show that inhibition of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a prostagl
17  by ubiquitously abrogating expression of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), a prostagl
18                     It is noteworthy that 15-hydroxyprostaglandin dehydrogenase (15-PGDH), an enzyme
19 c overexpression of PGE2-degrading enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH), resulted i
20         We identifed increased amounts of 15-hydroxyprostaglandin dehydrogenase (15-PGDH), the prosta
21 n of PGE(2) in tissue is NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
22 n of PGE(2) involves the NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
23 n the levels of the PGE2 catabolic enzyme 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
24 ation of PGE2 involves the NAD+-dependent 15-hydroxyprostaglandin dehydrogenase (15-PGDH).
25 , loss of the PGE(2)-catabolizing enzyme, 15-hydroxyprostaglandin dehydrogenase (15-PGDH, HPGD), in c
26 chanisms, including up-regulation of both 15-hydroxyprostaglandin dehydrogenase (15-PGDH, the key pro
27                                           15-Hydroxyprostaglandin dehydrogenase (15PGDH) is the prima
28  COX-2 (17.9-fold; P = 0.008) and reduced 15-hydroxyprostaglandin dehydrogenase (2.9-fold; P < 0.0001
29 -2 (COX-2) and enhanced the expression of 15-hydroxyprostaglandin dehydrogenase, a physiologic COX-2
30      With NAD+ as a cofactor, recombinant 15-hydroxyprostaglandin dehydrogenase acted as an 18-hydrox
31                                              Hydroxyprostaglandin dehydrogenase, an enzyme required f
32 e identity with the NADPH-dependent human 15-hydroxyprostaglandin dehydrogenase/carbonyl reductase.
33                                           15-hydroxyprostaglandin dehydrogenase degrades prostaglandi
34  cyclooxygenase 2-regulated synthesis and 15-hydroxyprostaglandin dehydrogenase-driven degradation an
35                                           15-Hydroxyprostaglandin dehydrogenase (HPGD) contributes to
36               Here, we found that the enzyme hydroxyprostaglandin dehydrogenase (HPGD), which catabol
37             In the heart, we propose that 15-hydroxyprostaglandin dehydrogenase inhibition triggers C
38                           Remarkably, the 15-hydroxyprostaglandin dehydrogenase inhibitor also revers
39                   PGE(2) stabilization by 15-hydroxyprostaglandin dehydrogenase inhibitor or EP2 or E
40          Stabilization of PGE(2) level by 15-hydroxyprostaglandin dehydrogenase inhibitor protected m
41 nthase-1, and inhibited the expression of 15-hydroxyprostaglandin dehydrogenase, leading to increased
42                   Significantly decreased 15-hydroxyprostaglandin dehydrogenase [NAD((+))], which deg
43                                   Minimal 15-hydroxyprostaglandin dehydrogenase oxidation of PGF(2 al
44   Pretreatment of the R15L cells with the 15-hydroxyprostaglandin dehydrogenase (PGDH) inhibitor 5-[[
45 , is inactivated by the catabolic enzyme, 15-hydroxyprostaglandin dehydrogenase (PGDH), which has tum
46 15-oxo-ETE) as a product from rabbit lung 15-hydroxyprostaglandin dehydrogenase (PGDH)-mediated oxida
47 found the predominantly cytosolic markers 15-hydroxyprostaglandin dehydrogenase, prostaglandins PGE2
48 al prostaglandin E synthase-1 and reduces 15-hydroxyprostaglandin dehydrogenase, resulting in prostag
49 triol also up-regulated the expression of 15-hydroxyprostaglandin dehydrogenase, the enzyme initiatin
50                                     Human 15-hydroxyprostaglandin dehydrogenase, the enzyme responsib
51 nd identified mutations in HPGD, encoding 15-hydroxyprostaglandin dehydrogenase, the main enzyme of p
52 inhibits the eicosanoid-degrading enzyme, 15-hydroxyprostaglandin dehydrogenase, was chosen for follo
53 (FZD6) and prostaglandin-metabolizing enzyme hydroxyprostaglandin dehydrogenase were increased in SCC
54  monocytes appears to be carried out by a 15-hydroxyprostaglandin dehydrogenase, which is present in
55 omise is illustrated by recent studies of 15-hydroxyprostaglandin dehydrogenase, which plays a critic